Get all premium features to the best stock analysis tool

Scholar Rock (SRRK) is transitioning from regulatory uncertainty to a clear execution path for a 2026 US launch of apitegromab. Resolution of FDA manufacturing concerns at Catalant's facility and resumed operations significantly de-risk the regulatory timeline for SRRK. A $550M non-dilutive debt facility and $370M cash position strengthen SRRK's balance sheet, minimizing dilution risk.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0.76 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024. (instead of Net loss per common share was $0.88 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024.) In the Conde.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent company de.

Redmile Group added 1,316,390 shares of Scholar Rock Holding Corporation in the fourth quarter; the estimated trade value was $49.37 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $84.58 million, reflecting both new purchases and stock price changes.